side effects of too much semaglutide GLP-1 drugs such as and tirzepatide are transforming obesity and diabetes care in India, but experts warn that improper use could lead to significant muscle loss. A new India-specific consensus highlights Your guide to GLP-1 side

Generation 1 Semaglutide (2017 / 2021)

cardiometabolic health

doi: 10.1007/s00125-002-1028-x 19 SchirraJNicolausMWoerleHJStruckmeierCKatschinskiMGkeBet al

iu ny c th xy ra do glutathione v vitamin cng c kh nng chng oxy ha

Oscier C, Bosley N, Milner Q: Paracetamol - A review of three routes of administration

mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation